Author Page for Douglas C. Palmer

Actions:

View:
Selected
Original List
All Versions Hide All Versions
All Abstracts Hide All Abstracts

(Rank)

Pan-Cancer Analysis in the Real-World Setting Uncovers Immunogenomic Drivers of Acquired Resistance Post-Immunotherapy

Number of pages: 52 Posted: 30 Jul 2025

Mohamed Reda Keddar, Sebastian Carrasco Pro, Roy Rabbie, Zeynep Kalender Atak, Ana Camelo Stewart, Scott A. Hammond, Douglas C. Palmer, Ross Stewart, Kathleen Burke, Ben Sidders, Jessica Davies, Jonathan Dry, Inigo Martincorena, Sajan Khosla, Adam J. Schoenfeld, Martin L. Miller and Sneak Peek Administrator

AstraZeneca Pharmaceuticals - UK, Boehringer Ingelheim Pharmaceuticals Inc, AstraZeneca Pharmaceuticals - UK, Quotient Therapeutics Inc, AstraZeneca Pharmaceuticals - UK, AstraZeneca Pharmaceuticals - AstraZeneca R&D, AstraZeneca Pharmaceuticals - AstraZeneca R&D, AstraZeneca Pharmaceuticals - UK, Tempus AI, Inc., Biorelate Ltd, AstraZeneca Farmaceutica Spain SA, Tempus AI, Inc., Wellcome Sanger Institute, AstraZeneca Pharmaceuticals - UK, Memorial Sloan Kettering Cancer Center, AstraZeneca Pharmaceuticals - UK and Independent

Downloads 38 (1,236,159)

Douglas C. Palmer

AstraZeneca Pharmaceuticals - AstraZeneca R&D

1

38

0

Scholarly Papers (1)

Pan-Cancer Analysis in the Real-World Setting Uncovers Immunogenomic Drivers of Acquired Resistance Post-Immunotherapy

Abstract: